Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F12%3A00060609" target="_blank" >RIV/00216224:14110/12:00060609 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.1016/j.lungcan.2012.05.073" target="_blank" >http://dx.doi.org/10.1016/j.lungcan.2012.05.073</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.lungcan.2012.05.073" target="_blank" >10.1016/j.lungcan.2012.05.073</a>

Result language

angličtina

Original language name

Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients

Original language description

The purpose of this trial was to evaluate the activity and feasibility of CBDCA together with full oral vinorelbin (NVBO) in 1st line treatment NSCLC patients. This is a prospective nerandomizovanou study of 259 patients.This is a prospective nerandomizovanou study of 259 patients.

Czech name

—

Czech description

—

Type

O - Miscellaneous

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2012

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů